Rituximab, interferon‐alfa‐2b and dose denseCVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of theLNH ‐PRO ‐05 study
British Journal of Haematology(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要